- Home
- ATXS vs MAZE Comparison
ATXS vs MAZE Comparison
Compare ATXS & MAZE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- MAZE
- Stock Information
- Founded
- ATXS 2008
- MAZE 2018
- Country
- ATXS United States
- MAZE United States
- Employees
- ATXS N/A
- MAZE N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- MAZE
- Sector
- ATXS Health Care
- MAZE
- Exchange
- ATXS Nasdaq
- MAZE NYSE
- Market Cap
- ATXS 401.2M
- MAZE 367.0M
- IPO Year
- ATXS 2015
- MAZE 2025
- Fundamental
- Price
- ATXS $4.76
- MAZE $10.01
- Analyst Decision
- ATXS Strong Buy
- MAZE Strong Buy
- Analyst Count
- ATXS 7
- MAZE 3
- Target Price
- ATXS $32.43
- MAZE $25.67
- AVG Volume (30 Days)
- ATXS 625.9K
- MAZE 104.1K
- Earning Date
- ATXS 05-13-2025
- MAZE 05-14-2025
- Dividend Yield
- ATXS N/A
- MAZE N/A
- EPS Growth
- ATXS N/A
- MAZE N/A
- EPS
- ATXS N/A
- MAZE 0.34
- Revenue
- ATXS N/A
- MAZE $167,500,000.00
- Revenue This Year
- ATXS N/A
- MAZE N/A
- Revenue Next Year
- ATXS N/A
- MAZE N/A
- P/E Ratio
- ATXS N/A
- MAZE $29.84
- Revenue Growth
- ATXS N/A
- MAZE N/A
- 52 Week Low
- ATXS $3.56
- MAZE $6.71
- 52 Week High
- ATXS $12.92
- MAZE $17.00
- Technical
- Relative Strength Index (RSI)
- ATXS 54.89
- MAZE N/A
- Support Level
- ATXS $3.83
- MAZE N/A
- Resistance Level
- ATXS $4.98
- MAZE N/A
- Average True Range (ATR)
- ATXS 0.45
- MAZE 0.00
- MACD
- ATXS 0.11
- MAZE 0.00
- Stochastic Oscillator
- ATXS 82.93
- MAZE 0.00
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About MAZE MAZE THERAPEUTICS INC
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.